Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ketty Peris

Showing results (431-440 of 533) with videos related to

Pageof 54
Sort By:
The Journal of Dermatological Treatment|February 27, 2024
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
Dermatology Practical & Conceptual|April 14, 2025
Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio ExperienceAnnunziata Dattola, Nicoletta Bernardini, Elena Campione, et al.
Patient Preference and Adherence|November 26, 2021
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in ItalyGiuseppe Argenziano, Paolo Amerio, Maria Grazia Aragone, et al.
The Journal of Dermatological Treatment|July 4, 2023
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter studyNiccolò Gori, Alvise Sernicola, Ersilia Tolino, et al.
Cancers|January 10, 2026
Diagnostic Performance of Line-Field Confocal Optical Coherence Tomography for Basal Cell Carcinoma: A Prospective StudyCarmen Orte Cano, Dilara Sanak, Clément Lenoir, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Cancers|July 29, 2023
Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International StudyPietro Sollena, Nikolaou Vasiliki, Elias Kotteas, et al.
European Journal of Dermatology : EJD|December 18, 2020
Hidradenitis suppurativa and adalimumab in the COVID-19 eraAngelo Valerio Marzano, Chiara Moltrasio, Giovanni Genovese, et al.
Transplantation Reviews (Orlando, Fla.)|July 8, 2021
Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus ConferenceJacopo Romagnoli, Luca Tagliaferri, Anna Acampora, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
Pageof 54

Showing results (431-440 of 533) with videos related to

Sort By:
Pageof 54
The Journal of Dermatological Treatment|February 27, 2024
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
Dermatology Practical & Conceptual|April 14, 2025
Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio ExperienceAnnunziata Dattola, Nicoletta Bernardini, Elena Campione, et al.
Patient Preference and Adherence|November 26, 2021
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in ItalyGiuseppe Argenziano, Paolo Amerio, Maria Grazia Aragone, et al.
The Journal of Dermatological Treatment|July 4, 2023
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter studyNiccolò Gori, Alvise Sernicola, Ersilia Tolino, et al.
Cancers|January 10, 2026
Diagnostic Performance of Line-Field Confocal Optical Coherence Tomography for Basal Cell Carcinoma: A Prospective StudyCarmen Orte Cano, Dilara Sanak, Clément Lenoir, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Cancers|July 29, 2023
Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International StudyPietro Sollena, Nikolaou Vasiliki, Elias Kotteas, et al.
European Journal of Dermatology : EJD|December 18, 2020
Hidradenitis suppurativa and adalimumab in the COVID-19 eraAngelo Valerio Marzano, Chiara Moltrasio, Giovanni Genovese, et al.
Transplantation Reviews (Orlando, Fla.)|July 8, 2021
Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus ConferenceJacopo Romagnoli, Luca Tagliaferri, Anna Acampora, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
Pageof 54